GU Cancers 2024 | EMBARK: subset analysis of enzalutamide versus leuprolide in prostate cancer

Neal Shore • 26 Jan 2024

GU Cancers 2024

Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, discusses results from the Phase III EMBARK trial (NCT02319837) of enzalutamide monotherapy, or enzalutamide with leuprolide against placebo and leuprolide in patients with high-risk biochemically recurrent prostate cancer. Treatment suspension occurred in the enzalutamide monotherapy arm based on serum PSA response, leading to similar metastasis-free survival (MFS) rates with the leuprolide arm in the suspension group. However, in the no-suspension group, enzalutamide and leuprolide demonstrated superior MFS. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

You know, we published our findings in the New England Journal in October of 2023, previously presented the first analysis at AUA 2023. At ASCO GU, this year, I presented a subset analysis of the enzyme monotherapy versus the LHRH alone comparison for the patients who underwent treatment suspension built into our trial design was in the three arm cohorts combination enza-LHR, enza mono, LHRH alone with a placebo...

I presented that data at a podium here at ASCO GU.